SubjectID,CRT_Score,True statement,TrueStatementID,IQE1,IQE2,IQE3,IQI1,IQI2,IQI3,IQU1,IQU2,IQU3,IQE_avg,IQI_avg,IQU_avg,False Difficult,False Easy,True_fleshes,difficult_fleshes,easy_fleshes,True_smog_index,difficult_smog_index,easy_smog_index,True_flesch_kincaid_grade,difficult_flesch_kincaid_grade,easy_flesch_kincaid_grade,True_coleman_liau_index,difficult_coleman_liau_index,easy_coleman_liau_index,True_automated_readability_index,difficult_automated_readability_index,easy_automated_readability_index,True_dale_chall_readability_score,difficult_dale_chall_readability_score,easy_dale_chall_readability_score,True_difficult_words,difficult_difficult_words,easy_difficult_words,True_linsear_write_formula,difficult_linsear_write_formula,easy_.linsear_write_formula,True_difficult_words,difficult_difficult_words,easy_difficult_words,True_gunning_fog,difficult_gunning_fog,easy_gunning_fog,True_text_standard,difficult_text_standard,easy_text_standard,Potential_Drop
R_1jJ8QGY6pz420R7,0.666666667,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells. ,1005,4,2,2,2,1,2,1,2,1,2.666666667,1.666666667,1.333333333,Intravenous recombiNo Statement herent ACE2 was reported as an ineffective therapy in severe COVID-19 by blocking the viral entry to target cells.,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the virus completely.,34.26,23.77,28.84,0,0,0,13.5,15.4,13.5,14.04,15.14,16.53,14.5,16.3,15.3,15.68,16.21,15.63,10,12,8,15,16,14.5,10,12,8,18,17.89,20.92,15,16,15,
R_1jJ8QGY6pz420R7,0.666666667,A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.,1006,5,5,4,4,2,4,4,4,4,4.666666667,3.333333333,4,A 5-day course of ivermectin was found to be safe and effective in treating child patients with mild COVID-19.,A 5-month course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.,77.57,77.57,77.57,0,0,0,7.2,7.2,7.2,9.86,9.86,10.5,10.9,10.9,11.4,12.06,11.23,12.06,4,4,4,10.5,10.5,10.5,4,4,4,9.71,9.71,9.71,10,11,11,
R_1jJ8QGY6pz420R7,0.666666667,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1013,2,2,2,2,2,2,2,2,2,2,2,2,A need for mechanical ventilation occurred in 31% of the aNo Statement herekinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was uNo Statement herettained in 63% of the aNo Statement herekinra-treated group compared with 27% of the control group,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from Ivermectin was attained in 63% of the anakinra-treated group compared with 27% of the control group,52.19,49.15,52.7,0,0,0,10.7,11.9,10.5,12.94,14.21,12.53,13.6,15.9,12.9,11.23,11.55,10.96,12,12,11,12.5,14,11.75,12,12,11,11.81,13.35,10.64,13,12,11,
R_1jJ8QGY6pz420R7,0.666666667,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as a therapeutic target for COVID-19.",1016,4,4,4,4,4,4,4,4,4,4,4,4,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate embryotic saline as a therapeutic target for COVID-19.","Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as the cause for COVID-19.",58.28,41.87,67.25,0,0,0,8.4,10.5,7,12.63,13.85,11.53,11.4,12.1,10.3,12.18,13.1,11.2,9,10,7,7.5,7.75,6.75,9,10,7,11.35,13,9.8,8,13,7,
R_1jJ8QGY6pz420R7,0.666666667,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19.  This suggests that chilblains might be a symptom of COVID-19.,1017,4,4,4,4,4,4,4,4,4,4,4,4,Microscopic abnormalities have been observed in both finger and toeNo Statement hereils of patients with COVID-19. This suggests that heart disease might be a symptom of COVID-19.,Microscopic abnormalities have been observed in both stool samples and urine of patients with COVID-19. This suggests that chilblains might be a symptom of COVID-19.,67.76,66.23,67.25,0,0,0,6.8,7.4,7,14.2,14.14,13.62,11.7,12,11.4,10.81,11.32,11.2,7,8,7,6,6.75,6.25,7,8,7,8.13,8.36,8.2,7,7,7,
R_1jTmBto8yBSympt,1,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells. ,1005,4,4,4,4,4,4,4,4,4,4,4,4,Intravenous recombiNo Statement herent ACE2 was reported as a non-effective therapy in severe COVID-19 because it was not able to block the viral entry to target cells.,"Intravenous recombinant ACE2 is not a real therapy, even though it was supposedly reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells.",34.26,35.61,25.12,0,0,0,13.5,15,17,14.04,12.89,12.72,14.5,16.8,17.4,15.68,14.33,13.24,10,11,11,15,18.5,21.5,10,11,11,18,18.21,19.88,15,15,13,
R_1jTmBto8yBSympt,1,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.",1010,2,2,2,4,4,4,4,4,4,2,4,4,"We have not reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies usually cannot be performed 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.","We cannot reach consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days prior to any potential infectious contact, given that most exposed individuals will not have have begun to produce antibodies by then.",17.17,16.15,14.63,0,0,0,17.9,18.3,18.9,17.12,16.95,16.14,21,21.1,21.2,12.53,12.33,12.05,19,19,20,22.25,22.75,23.5,19,19,20,19.82,19.94,20.14,18,13,19,
R_1jTmBto8yBSympt,1,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of early identification of asymptomatic carriers.",1014,4,4,4,4,4,4,4,4,4,4,4,4,"We evaluated 298 persons and identified twelve negative cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data tells us it is not important to identify asymptomatic carriers early on.","We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were symptomatic, while only 25% of positive cases reported symptoms that hardly ever included fever, diarrhea, and cough. Our data does not confirm the importance of early identification of asymptomatic carriers.",32.19,39.63,30.87,15,15,15,12.2,11.4,12.7,15.25,12.58,14.38,13.2,11.5,13.1,11.25,10.83,11.05,15,14,16,11.16666667,11.66666667,11.83333333,15,14,16,15.24,14.97,15.78,12,12,12,
R_1jTmBto8yBSympt,1,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19.  This suggests that chilblains might be a symptom of COVID-19.,1017,4,2,4,4,4,4,4,4,4,3.333333333,4,4,Microscopic abnormalities have been observed in only toeNo Statement hereils of patients with COVID-19. This suggests that chilblains is not a symptom of COVID-19.,Microscopic abnormalities will never be observed in finger and toenails of patients with COVID-19. This suggests that chilblains might be a symptom of COVID-19.,67.76,67.76,59.3,0,0,0,6.8,6.8,8,14.2,14.72,13.96,11.7,12,11.5,10.81,12.13,10.81,7,7,7,6,6,6,7,7,7,8.13,8.13,8.13,7,12,8,
R_1jTmBto8yBSympt,1,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, and evidence of confirmed cases in the neighbourhood could help discriminate infected patients from uninfected.",1018,4,4,4,4,4,4,4,4,4,4,4,4,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (joint pain), household, cluster, and evidence of confirmed cases in the workplace could spread illness to patients who tested negative.","We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (joint pain), household cluster, and evidence of no confirmed cases at the neighborhood pharmacy could help keep infected patients from telling others they tested positive..",24.11,31.56,18.02,0,0,0,23.6,22.8,25.9,13.65,12.2,12.9,32.2,31.5,34.5,12.68,12.9,13.13,17,17,18,33.5,31,36.5,17,17,18,25.64,23.83,27.02,13,13,13,
R_1l495aVZStFWvp9,1,"COVID-19 patients with recurrent epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.",1019,3,3,3,3,3,3,3,3,3,3,3,3,"COVID-19 vacciNo Statement hereted patients with recurrent epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.","COVID-19 patients with recurrent epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical  laugh, which may lead to a worse prognosis.",42.72,41.19,42.72,0,0,0,12.3,12.9,12.3,18.39,19.03,18.1,18.4,19.6,18,10.94,11.68,10.94,12,14,12,13.5,14.75,13.5,12,14,12,13,14.18,13,13,20,13,
R_1l495aVZStFWvp9,1,"While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",1020,3,3,3,3,3,3,3,3,3,3,3,3,"While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing major infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.","While molecular testing has been the primary means of diagnosing acute COVID-19 infection, testicular testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",10.91,10.91,2.45,0,0,0,22.4,22.4,23.6,17.19,17.19,17.89,27.7,27.7,28.2,13.85,13.48,14.22,16,15,17,32.5,32.5,33.5,16,15,17,26.5,26.5,27.43,0,13,24,
R_1l495aVZStFWvp9,1,"150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",1031,2,3,4,3,2,3,2,3,4,3,2.666666667,3,"150 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 6 days versus 10 days, and median time to clinical cure was 4 days versus 6 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.","480 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",61.67,60.65,60.65,11.2,11.2,11.2,9.1,9.5,9.5,10.15,9.69,9.57,10.8,10.6,10.5,10.67,10.4,10.4,13,13,13,11,11.5,11.5,13,13,13,10.9,11.11,11.11,11,10,10,
R_1l495aVZStFWvp9,1,"A substantial number of infected healthcare workers were asymptomatic 28.9%, and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vaccinated against seasonal influenza.",1074,3,3,3,3,3,3,3,3,3,3,3,3,"A substantial number of infected healthcare workers were asymptomatic (28.9%), and 35.5% were admitted to hospital. The mean length of hospital stay was 11 days. 70.1% of confirmed cases had been vacciNo Statement hereted against seasoNo Statement herel influenza.","A substantial number of infected healthcare workers were asymptomatic (28.9%), and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vaccinated against seasonal rashes.",55.91,63.56,55.91,10.8,10.4,10.4,7.2,6.3,7.2,11.2,12.19,10.74,8.9,9.7,8.7,12.56,12.93,12.56,11,13,11,4.3,4.5,4.1,11,13,11,10.8,9.27,9.66,11,10,10,
R_1l495aVZStFWvp9,1,"Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",1160,3,4,5,3,3,4,2,3,4,4,3.333333333,3,"Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 85.4%, 94.3%, 79.0% and 71.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.","Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 32 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",69.89,69.89,69.89,10,10,10,6,6,6,7.11,7.11,7.11,6.3,6.3,6.3,12.59,12.59,12.59,14,14,14,5.357142857,5.357142857,5.357142857,14,14,14,9.76,9.76,9.76,6,6,6,
R_1nQ8DUnSs5SgtDG,0.333333333,A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.,1006,4,2,4,4,4,4,4,4,4,3.333333333,4,4,you could possibly get rid of covid in 5 days dues ivermectin only if you have a mild case of covid19 and are only an adult,ivermectin can help adult with mid covid19,77.57,78.93,106.67,0,0,0,7.2,8.7,0.1,9.86,4.88,9.87,10.9,9.3,6.3,12.06,10.39,13.01,4,2,1,10.5,14,2.5,4,2,1,9.71,11.94,2.8,10,9,3,
R_1nQ8DUnSs5SgtDG,0.333333333,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of early identification of asymptomatic carriers.",1014,4,4,3,2,2,3,4,4,4,3.666666667,2.333333333,4,298 all have covid we have yet to figure out who is symptomatic or not but mostly everyone does not have symptoms,25% of people tested are showing symptoms of Covid19 while the others aren't but they still have covid,32.19,74.53,78.59,15,0,0,12.2,8.3,6.8,15.25,6.96,9.16,13.2,9.3,9.8,11.25,7.6,10.67,15,2,4,11.16666667,13,8,15,2,4,15.24,10.62,7.2,12,8,7,
R_2PBti6jAC6ntkMN,0.666666667,"While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalised patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of non-hospitalised patients. Antibody levels were initially low, increased over time, and increased as the disease got worse. ",1024,4,2,5,3,3,4,5,5,3,3.666666667,3.333333333,4.333333333,"While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalized patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of non-hospitalized patients. Antibody levels were initially low, increased over time, and increased as the disease got worse.","While Test A failed to detect SARS antibodies in non-hospitalized patients, Test B detected antibodies in most . Test C detected antibodies in 95% of non-hospitalized patients. Antibody levels were initially low, increased over time, and increased as the disease got worse.",48.5,48.5,40.65,13,13,13,10,10,11,13.27,13.27,13.68,12.6,12.6,12.1,12.06,12.06,10.48,10,10,10,10.16666667,10.16666667,9,10,10,10,10.37,10.37,10.36,13,13,11,
R_2PBti6jAC6ntkMN,0.666666667,"150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",1031,3,3,3,2,2,1,3,2,2,3,1.666666667,2.333333333,"150 patients were randomized to be on the favipiravir group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.","150 patients were randomized to be in the control group. Median time to the end of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",61.67,61.67,70.84,11.2,11.2,10.5,9.1,9.1,7.7,10.15,9.63,7.94,10.8,10.3,8.7,10.67,10.67,10.57,13,13,12,11,11,10.33333333,13,13,12,10.9,10.9,10,11,11,11,
R_2PBti6jAC6ntkMN,0.666666667,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.",1080,3,1,4,3,3,2,3,2,3,2.666666667,2.666666667,2.666666667,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with a increased risk of infection",Frequent contact with patients and those exposed to patients with  symptoms are associated with many increased risk of infection,50.16,50.16,43.73,0,0,0,11.5,11.5,11.9,15.03,14.74,16.01,15.8,15.3,15.1,11.45,11.45,12.06,8,8,8,12.5,12.5,11.5,8,8,8,12.21,12.21,11.81,12,12,12,
R_2PBti6jAC6ntkMN,0.666666667,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,1154,3,3,4,4,4,4,4,5,4,3.333333333,4,4.333333333,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,Weight gain was present in most patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,68.47,68.47,62.04,9.7,9.7,9.7,6.5,6.5,6.9,13.61,13.61,16.38,11.3,11.3,12.9,10.23,10.23,10.3,7,7,7,6,6,5,7,7,7,9.23,9.23,9.43,10,10,10,
R_2PBti6jAC6ntkMN,0.666666667,"The COVID-19 epidemic could be controlled by alternating one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coronavirus impact on economy.",1180,3,3,4,5,4,4,4,4,4,3.333333333,4.333333333,4,"The COVID-19 epidemic could be controlled by alterNo Statement hereting one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well controlled, could be important also to alleviate coroNo Statement herevirus impact on economy.","The COVID-19 epidemic could be manipulated by alternating one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to eliminate coronavirus impact on economy.",40.18,46.61,40.18,0,0,0,13.2,12.8,13.2,14.74,14.86,14.86,16.3,17.3,16.4,11.42,11.62,11.42,14,15,14,15.75,15.75,16.25,14,15,14,16.11,14.7,17,16,15,17,
R_2pRnDAFCtzZ7iXB,0.333333333,"Observations so far suggest a mean incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and decreases over the following 78 days in most patients.",1026,3,4,5,5,5,4,5,5,5,4,4.666666667,5,"Observations so far suggest a mean incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNo Statement here is detectable in the airways 23 days before the onset of symptoms, at the onset of symptoms, and increases over the following 78 days in most patients.","Observations so far suggest a mean incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and increases over the following 78 days in most patients.",43.56,43.06,43.56,0,0,0,14,14.2,14,9.58,9.93,9.58,14.5,15,14.5,11.32,11.23,11.32,13,14,13,18.25,18.5,18.25,13,14,13,15.36,15.49,15.36,15,15,15,
R_2pRnDAFCtzZ7iXB,0.333333333,"Migrant worker cases were younger, had few medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia decreased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.",1028,1,2,4,4,4,4,4,5,4,2.333333333,4,4.333333333,"Migrant worker cases were older, had lots medical comorbidities and more severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia increased, whilst patients presenting earlier in their illness and asymptomatic disease became less common.","Migrant worker cases were younger, had few medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia increased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.",34.76,34.76,34.76,0,0,0,13.3,13.3,13.3,17.69,17.52,17.69,17.3,17.2,17.3,11.89,11.89,11.49,16,16,15,13.25,13.25,13.25,16,16,15,14.98,14.98,14.98,12,12,18,
R_2pRnDAFCtzZ7iXB,0.333333333,"The median duration of COVID-19 was shorter in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days). ",1094,2,1,4,4,4,2,4,4,4,2.333333333,3.333333333,4,"The median duration of COVID-19 was longer in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days).","The true median duration of COVID-19 was not actually shorter in the thalidomide group compared to the control group as you can see here (respectively, 11.0 vs 23.0 days).",69.28,69.28,65.22,0,0,0,6.2,6.2,7.8,10.53,10.24,9.33,9.2,8.9,9,14.68,14.68,12.52,7,6,8,5.75,5.75,8.25,7,6,8,9.91,9.91,11.32,6,6,9,
R_2pRnDAFCtzZ7iXB,0.333333333,"When each vitamin D status group was considered, 69.44% of the vitamin D deficient group had severe COVID-19 and 81.82% of the severely deficient group had severe COVID-19.",1151,4,4,4,3,2,3,3,2,3,4,2.666666667,2.666666667,"When each vitamin D status group was considered, 69.44% of the severely vitamin D deficient group had severe COVID-19 and 81.82% of the deficient group had severe COVID-19.","When each vitamin D deficient status group was considered, 69.44% of the non deficient vitamin D deficient group had severe COVID-19 and 81.82% of the non-severely deficient group had severe COVID-19.",70.5,70.5,61.02,11.2,11.2,12.5,5.7,5.7,7.3,9.31,9.31,11.34,7.6,7.6,9.5,11.43,11.43,11.28,6,6,6,5.666666667,5.666666667,6.833333333,6,6,6,9.43,9.43,9.28,6,6,7,
R_2pRnDAFCtzZ7iXB,0.333333333,Early nutritional screening is therefore an important step in order to perform an adequate nutritional intervention as part of COVID-19 management.,1152,5,5,4,4,4,4,4,4,4,4.666666667,4,4,Early nutritioNo Statement herel screening is therefore a non-important step in order to perform an adequate nutritioNo Statement herel intervention as part of COVID-19 maNo Statement heregement.,Early nutritional screening is therefore an important step in order to perform an un-adequate nutritional intervention as part of COVID-19 management.,16.32,18.69,16.32,0,0,0,16.2,17.4,16.2,17.23,18.69,17.81,17.6,21.6,18.2,11.45,12.58,12.2,7,9,7,16.5,18.5,16.5,7,9,7,16.02,15.24,16.02,17,19,17,
R_2Sdw9JahxnpIfIO,0.333333333,"A substantial number of infected healthcare workers were asymptomatic 28.9%, and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vaccinated against seasonal influenza.",1074,4,4,4,4,4,4,4,4,4,4,4,4,"A substantial number of uncontamiNo Statement hereted healthcare workers were asymptomatic (28.9%), and 35.5% were admitted to hospital.",The mean length of hospital stay was 8.1 days. 70.1% of possible cases had been vaccinated against seasonal influenza.,55.91,48.47,61.83,10.8,10.5,0,7.2,8,7,11.2,14.95,9.94,8.9,12.7,8.1,12.56,14.46,10.76,11,7,4,4.3,3.666666667,6.25,11,7,4,10.8,11.29,10.12,11,11,7,
R_2Sdw9JahxnpIfIO,0.333333333,Children with serious underlying medical conditions had a 1.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 2.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 2.81 times higher risk of death from COVID-19 compared to healthy children.,1088,2,2,4,4,4,4,4,4,3,2.666666667,4,3.666666667,Heathy Children with serious underlying medical conditions had a 1.79 times higher risk of death from COVID-19 than obese children with severe health conditions.,Children with obesity were found to be 2.87 times less likely to get severe COVID-19 than healthy children.,70.5,59.3,87.72,9.3,0,0,5.7,8,3.3,11.28,14.49,8.96,8.6,11.7,6.6,8.89,13.44,10.22,8,6,2,4.833333333,7.5,4,8,6,2,7.29,11.47,5.82,9,8,4,
R_2Sdw9JahxnpIfIO,0.333333333,"The median duration of COVID-19 was shorter in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days). ",1094,4,4,4,4,4,4,4,4,4,4,4,4,"The median duration of COVID-19 was shorter in the Phenothiazines group compared to the control group (respectively, 11.0 vs 23.0 days).","The median duration of COVID-19 was longer in the sick group compared to the control group (respectively, 11.0 vs 23.0 days).",69.28,60.82,77.74,0,0,0,6.2,7.4,5,10.53,11.34,8.33,9.2,9.8,7.4,14.68,14.68,13.93,7,7,5,5.75,6.25,5.75,7,7,5,9.91,11.82,9.91,6,12,5,
R_2Sdw9JahxnpIfIO,0.333333333,Patients hospitalized and in the ICU because of COVID-19 have a higher metabolism and require more calories than their non-COVID counterparts.,1153,4,4,4,4,3,4,4,4,4,4,3.666666667,4,Patients hospitalized and in the ICU because of prior health conditions and COVID-19 have a higher metabolism and require more calories than their non-COVID counterparts.,Patients hospitalized and in the ICU because of COVID-19 have a higher metabolism and require less calories than their non-COVID counterparts.,41.7,37.64,41.7,0,0,0,12.7,14.2,12.7,15.61,16.19,15.61,16.4,18.6,16.4,12.95,13.09,12.95,7,9,7,13.5,16.5,13.5,7,9,7,14.11,16.4,14.11,13,17,13,
R_2Sdw9JahxnpIfIO,0.333333333,"The COVID-19 epidemic could be controlled by alternating one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coronavirus impact on economy.",1180,4,3,4,4,3,4,4,4,4,3.666666667,3.666666667,4,"The COVID-19 epidemic could be controlled by alterNo Statement hereting one or two weeks of complete lockdown with one or two months of partial freedom, respectively.","Control strategies of this kind, where the lockdowns duration is forced could be important also to alleviate coronavirus impact on economy.",40.18,53.55,33.24,0,0,0,13.2,12.3,13.8,14.74,13.81,15.03,16.3,17.1,16,11.42,12.82,12.2,14,8,8,15.75,16,15.5,14,8,8,16.11,15.02,16.02,16,13,16,
R_2SoR53DN4MQOqEN,0,"While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",1020,4,2,4,4,2,4,4,4,4,3.333333333,3.333333333,4,"While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.","While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",10.91,10.91,10.91,0,0,0,22.4,22.4,22.4,17.19,17.19,17.19,27.7,27.7,27.7,13.85,13.85,13.85,16,16,16,32.5,32.5,32.5,16,16,16,26.5,26.5,26.5,0,0,0,1
R_2SoR53DN4MQOqEN,0,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",1027,4,2,4,4,2,4,4,4,4,3.333333333,3.333333333,4,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.","Among those with moderate COVID-19 disease, time to clinical improvement was 20 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",52.53,52.53,52.53,0,0,0,12.6,12.6,12.6,10.39,10.39,10.51,15,15,15.1,10.53,10.53,10.53,13,13,13,17,17,17,13,13,13,14.5,14.5,14.5,15,15,11,1
R_2SoR53DN4MQOqEN,0,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects. ",1090,4,2,4,4,2,4,4,4,4,3.333333333,3.333333333,4,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years and doctors guaranteed that if children 12-15 years of age got the SARS-CoV-2 they were practically immune to COVID compared to other vacciNo Statement heretions.","There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years and they are completely immune to COVID.",57.61,50.5,59.64,0,0,0,10.7,13.4,9.9,12.01,13.41,11.72,14.2,18.2,12.8,11.55,11.61,11.73,11,16,10,14,18,12.5,11,16,10,13.35,16.43,13,14,18,13,1
R_2SoR53DN4MQOqEN,0,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,1154,4,2,4,4,2,4,4,4,4,3.333333333,3.333333333,4,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,68.47,68.47,68.47,9.7,9.7,9.7,6.5,6.5,6.5,13.61,13.61,13.61,11.3,11.3,11.3,10.23,10.23,10.23,7,7,7,6,6,6,7,7,7,9.23,9.23,9.23,10,10,10,1
R_2SoR53DN4MQOqEN,0,"Compared to White respondents, American Indian/Alaska Native and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being extremely likely to be vaccinated.",1164,4,2,4,4,2,4,4,4,4,3.333333333,3.333333333,4,"Compared to White respondents, American Indian/Alaska No Statement heretive and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being extremely likely to be vacciNo Statement hereted.","Compared to White respondents, American Indian/Alaska Native and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being extremely likely to be vaccinated.",6.17,10.57,6.17,0,0,0,20.1,20.5,20.1,20.55,20.61,20.55,25.2,27.2,25.2,10.78,11.24,10.78,9,10,9,24.5,26.5,24.5,9,10,9,16.27,17.43,16.27,21,21,21,1
R_2uCFUfHPud4JQgS,0.666666667,"Observations so far suggest a mean incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and decreases over the following 78 days in most patients.",1026,3,3,3,4,4,4,4,4,4,3,4,4,"Studies show that the average incubation period in 5 days. However, viral RNo Statement here can be found in the airways as quick as 2 minutes after exposure",Studies show that the average incubation period is 5 days. This means that the average person must be exposed to COVID for around 5 days in order to contract it,43.56,57.27,64.71,0,0,0,14,8.8,8,9.58,8.63,7.24,14.5,7.4,6.7,11.32,11.66,9.12,13,9,6,18.25,8.5,8.5,13,9,6,15.36,11.31,10,15,9,8,
R_2uCFUfHPud4JQgS,0.666666667,"Oxygen saturation in central venous blood, oxygen consumption and oxygen extraction are good predictors of mortality in critically ill patients with COVID-19.",1072,2,2,1,2,2,2,1,1,2,1.666666667,2,1.333333333,"Oxygen saturation in central venous blood, oxygen consumption, and oxygen extraction have no relation with mortality in ill COVID patients",critical COVID patients are likely to show oxygen saturation in central venous blood,15.31,25.8,41.36,0,0,0,16.6,14.6,10.7,18.04,16.65,13.96,18.9,16.6,11.2,13.34,12.52,12.78,10,9,6,17,15,7.5,10,9,6,19.71,18,11.35,17,15,11,
R_2uCFUfHPud4JQgS,0.666666667,"When each vitamin D status group was considered, 69.44% of the vitamin D deficient group had severe COVID-19 and 81.82% of the severely deficient group had severe COVID-19.",1151,3,3,3,4,4,4,4,4,4,3,4,4,Studies show that people more deficient with Vitamin D are less susceptible to COVID 19,Studies show that people who get more sun are 99.9% less likely to suffer severe COVID symptoms,70.5,56.25,79.77,11.2,0,0,5.7,9.1,4.2,9.31,10.37,6.92,7.6,9,4.7,11.43,11.75,9.63,6,4,3,5.666666667,10.5,3.25,6,4,3,9.43,14,3.4,6,9,4,
R_2uCFUfHPud4JQgS,0.666666667,Early nutritional screening is therefore an important step in order to perform an adequate nutritional intervention as part of COVID-19 management.,1152,3,3,3,4,4,4,4,4,4,3,4,4,NutritioNo Statement herel screening is important to watch in the recovery of COVID patients.,Studies show that poor Nutrition could be related to the cause of COVID,16.32,48.81,75.2,0,0,0,16.2,9.9,6,17.23,14.84,8.16,17.6,12.5,6.5,11.45,12.23,9.14,7,6,3,16.5,9,7.5,7,6,3,16.02,11.31,11.35,17,13,7,
R_2uCFUfHPud4JQgS,0.666666667,"Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",1160,2,2,3,4,4,4,4,4,4,2.333333333,4,4,A study of blood types related to COVID related ICU patients showed that 9.1% was the average mortality rate among them. It also found that Rh phenotype can change the results by a scale of almost 83% more.,"Of the patients admitted in the ICU, people with O type blood have a 0% mortality rate. On the other hand, A, B, and AB have nearly a 100%",69.89,75.5,82.14,10,10.5,0,6,5.9,5.4,7.11,6.89,2.72,6.3,5.9,3.7,12.59,10.5,9.8,14,6,3,5.357142857,7,7.25,14,6,3,9.76,9.29,8.56,6,7,6,
R_2Y2GtLl5aWGbwNQ,0.333333333,"Observations so far suggest a mean incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and decreases over the following 78 days in most patients.",1026,4,4,4,4,4,4,4,4,4,4,4,4,"Observations so far suggest a median incubation period of 5 days and a mean incubation period of 45 days from exposure to the onset of symptoms. Viral RNo Statement here is not detectable in airways before the onset of symptoms, only detectable at the onset of symptoms, and does not decrease until after 78 days in most patients.","Observations so far suggest a incubation period of 156 days and not noticable incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is like mabye in the airways 23 days before the onset of symptoms, pretty large at the onset of symptoms, and gets a wee bit smaller over the following 200-300 days in most patients.",43.56,42.04,48.98,0,0,0,14,14.6,14,9.58,10.22,9.35,14.5,15.4,15.5,11.32,10.52,11.1,13,14,12,18.25,18,19.25,13,14,12,15.36,15.05,15.48,15,15,16,
R_2Y2GtLl5aWGbwNQ,0.333333333,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",1027,4,4,4,4,4,4,4,4,4,4,4,4,"Among those with severe COVID-19 disease, time to clinical improvement was over 7 days in the CBP group, versus under 8 days in the control group. The data show that administration of CBP is a less effective treatment option for patients with COVID-19 disease with an unfavorable outcome in the rate of, and time to, clinical improvement.","Among those with moderate CORBID-19 disease, time to clinical improvement was maybe a week in the CBP group, versus over but cloase to two weeks in the control group. The data show that administration of CBP is a non legit treatment option for patients with CORPID-20 disease with a favorable outcome in the rate of and time to and clinical improvement.",52.53,51.01,48.98,0,0,0,12.6,13.2,14,10.39,10.91,10.57,15,16.1,16.4,10.53,10.59,10.84,13,14,16,17,17.75,18.75,13,14,16,14.5,14.91,15.48,15,11,11,
R_2Y2GtLl5aWGbwNQ,0.333333333,Children with serious underlying medical conditions had a 1.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 2.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 2.81 times higher risk of death from COVID-19 compared to healthy children.,1088,4,4,4,4,5,4,4,5,4,4,4.333333333,4.333333333,Children with serious underlying medical conditions had a 1.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 2.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 2.81 times higher risk of death from COVID-19 compared to healthy children.,Children with serious underlying medical conditions had a 1.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 2.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 2.81 times higher risk of death from COVID-19 compared to healthy children.,70.5,70.5,70.5,9.3,9.3,9.3,5.7,5.7,5.7,11.28,11.28,11.28,8.6,8.6,8.6,8.89,8.89,8.89,8,8,8,4.833333333,4.833333333,4.833333333,8,8,8,7.29,7.29,7.29,9,9,9,
R_2Y2GtLl5aWGbwNQ,0.333333333,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,1154,3,2,4,4,3,2,3,4,4,3,3,3.666666667,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,68.47,68.47,68.47,9.7,9.7,9.7,6.5,6.5,6.5,13.61,13.61,13.61,11.3,11.3,11.3,10.23,10.23,10.23,7,7,7,6,6,6,7,7,7,9.23,9.23,9.23,10,10,10,
R_2Y2GtLl5aWGbwNQ,0.333333333,"The COVID-19 epidemic could be controlled by alternating one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coronavirus impact on economy.",1180,2,3,4,4,3,3,4,3,4,3,3.333333333,3.666666667,"The COVID-19 epidemic could be controlled by alterNo Statement hereting one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coroNo Statement herevirus impact on economy.","The COVID-19 epidemic could be controlled by alternating one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coronavirus impact on economy.",40.18,46.61,40.18,0,0,0,13.2,12.8,13.2,14.74,15.21,14.74,16.3,17.6,16.3,11.42,11.94,11.42,14,16,14,15.75,16.25,15.75,14,16,14,16.11,15.51,16.11,16,16,16,
R_2YY52wmLbl7gAPw,0.666666667,"COVID-19 patients with recurrent epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.",1019,4,2,4,4,3,4,3,4,3,3.333333333,3.666666667,3.333333333,"COVID-19 patients with recurrent epileptic seizures had more underlying neurological diseases than patients who didn´t have an epilepsy history but with a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.","COVID-19 patients with recurrent epileptic seizures had less underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.",42.72,42.21,42.72,0,0,0,12.3,12.5,12.3,18.39,17.93,18.39,18.4,18.4,18.4,10.94,11.59,10.94,12,12,12,13.5,13.75,13.5,12,12,12,13,13.08,13,13,13,13,
R_2YY52wmLbl7gAPw,0.666666667,"Oxygen saturation in central venous blood, oxygen consumption and oxygen extraction are good predictors of mortality in critically ill patients with COVID-19.",1072,3,3,4,4,4,4,4,4,4,3.333333333,4,4,"Oxygen saturation in central venous blood, oxygen consumption, and oxygen extraction are good signs of critically ill patients with COVID-19.","Oxygen saturation in central venous blood, oxygen consumption, and oxygen extraction are bad predictors of mortality in critically ill patients with COVID-19.",15.31,34.26,15.31,0,0,0,16.6,13.5,16.6,18.04,16.94,17.81,18.9,17.3,18.9,13.34,13.31,13.34,10,8,10,17,14,17,10,8,10,19.71,16,19.71,17,14,17,
R_2YY52wmLbl7gAPw,0.666666667,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects. ",1090,3,2,4,4,3,3,4,4,4,3,3.333333333,4,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 813 years, although the study was too small to identify any rare side-effects.","There appears to be an age gradient, with younger children seemingly more susceptible to SARS-CoV-2 and more likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects.",57.61,57.61,57.61,0,0,0,10.7,10.7,10.7,12.01,11.84,12.01,14.2,14.1,14.2,11.55,11.55,11.55,11,11,11,14,14,14,11,11,11,13.35,13.35,13.35,14,12,14,
R_2YY52wmLbl7gAPw,0.666666667,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are common and associated with greater severity of illness.,1150,3,2,3,4,3,4,4,3,4,2.666666667,3.666666667,3.666666667,Early experience with COVID-19 patients suggests that intestiNo Statement herel symptoms are common and associated with greater severity of illness.,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are not common and not associated with greater severity of illness.,19.37,17.34,25.8,0,0,0,15,15.8,14.6,21.11,19.55,19.26,19.5,18.9,18.7,15.06,15.68,14.1,9,11,9,13,14,14,9,11,9,16.09,16,16,15,16,15,
R_2YY52wmLbl7gAPw,0.666666667,Early nutritional screening is therefore an important step in order to perform an adequate nutritional intervention as part of COVID-19 management.,1152,2,2,4,4,4,4,4,4,4,2.666666667,4,4,Early screening is therefore an important step in order to perform an adequate intervention as part of nutritioNo Statement herel maNo Statement heregement.,Early nutritional screening is therefore an unimportant step in order to perform an adequate nutritional intervention as part of nutritional management.,16.32,31.21,7.86,0,0,0,16.2,14.6,17.4,17.23,16.54,18.91,17.6,17.5,18.7,11.45,11.64,10.69,7,9,8,16.5,15.5,17.5,7,9,8,16.02,14.42,17.92,17,15,18,
R_2ZKAA8Zes0Wu838,0.666666667,"COVID-19 patients with recurrent epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.",1019,3,3,3,3,3,3,3,3,3,3,3,3,"COVID-19 patients with recurrent epileptic seizures had less underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.","COVID-19 patients without problems had less underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a way better prognosis.",42.72,42.72,43.22,0,0,0,12.3,12.3,12.1,18.39,18.39,17.69,18.4,18.4,17.6,10.94,10.94,11.49,12,12,13,13.5,13.5,12.75,12,12,13,13,13,12.93,13,13,13,
R_2ZKAA8Zes0Wu838,0.666666667,"Observations so far suggest a mean incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and decreases over the following 78 days in most patients.",1026,3,3,2,2,2,2,2,4,2,2.666666667,2,2.666666667,"Observations so far suggest a max incubation period of 5 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNo Statement here is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and decreases over the following 78 days in all patients.","Observations so far suggest a mean incubation period of 50 days and median incubation period of 45 days from exposure to the onset of symptoms. Viral RNA is detectable in the airways 23 days before the onset of symptoms, peaks at the onset of symptoms, and decreases over the following 78 days in most patients.",43.56,42.55,43.56,0,0,0,14,14.4,14,9.58,9.75,9.7,14.5,15.1,14.3,11.32,11.7,10.74,13,14,13,18.25,18.75,18.25,13,14,13,15.36,15.61,15.36,15,16,14,
R_2ZKAA8Zes0Wu838,0.666666667,"Oxygen saturation in central venous blood, oxygen consumption and oxygen extraction are good predictors of mortality in critically ill patients with COVID-19.",1072,3,3,4,2,2,4,2,4,3,3.333333333,2.666666667,3,"Oxygen saturation in central venous blood, oxygen consumption, and oxygen extraction are poor predictors of mortality in critically ill patients with COVID-19.","Oxygen saturation in central venous blood, oxygen consumption, and oxygen extraction are poor predictors of mortality in critically ill patients that have never contracted COVID-19.",15.31,15.31,12.26,0,0,0,16.6,16.6,17.8,18.04,18.04,18.51,18.9,19.1,20.6,13.34,13.34,13.09,10,10,11,17,17,19.5,10,10,11,19.71,19.71,21.2,17,17,21,
R_2ZKAA8Zes0Wu838,0.666666667,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.",1080,3,3,3,3,3,3,3,3,3,3,3,3,"Close, infrequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.",No contact with patients or those exposed to patients with cough symptoms are associated with an increased risk of infection.,50.16,41.7,51.18,0,0,0,11.5,12.7,11.1,15.03,15.61,13.17,15.8,16.2,13.5,11.45,11.45,10.94,8,8,7,12.5,13.5,12,8,8,7,12.21,14.11,12,12,16,12,
R_2ZKAA8Zes0Wu838,0.666666667,"Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",1160,3,2,1,3,2,2,3,3,4,2,2.333333333,3.333333333,"Of all the patients, 91% required admission to the intensive care unit (ICU), of whom 8.3% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 8.64%, 9.33%, 8.0% and 7.08%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.","Of all the patients, 100% required admission to the intensive care unit (ICU), of whom 100% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 100% , 100% , 100%  and 100% , respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",69.89,68.26,62.38,10,10.5,12.2,6,6.6,8.9,7.11,7.35,8.47,6.3,7.1,9.8,12.59,12.22,10.9,14,14,14,5.357142857,6.416666667,11.5,14,14,14,9.76,10.4,12.72,6,7,9,
R_3eb2ZyQGDg0SpBf,1,"While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalised patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of non-hospitalised patients. Antibody levels were initially low, increased over time, and increased as the disease got worse. ",1024,5,4,4,4,3,3,4,3,4,4.333333333,3.333333333,3.666666667,"While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalized patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of hospitalized patients. Antibody levels were initially low, increased over time, and increased as the disease got worse","While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalized patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of non-hospitalized patients. Antibody levels were initially high, decreased over time, and decreased as the disease got worse",48.5,48.5,48.5,13,13,13,10,10,10,13.27,12.87,13.45,12.6,12,12.6,12.06,12.06,12.06,10,10,10,10.16666667,10.16666667,10.16666667,10,10,10,10.37,10.37,10.37,13,13,13,
R_3eb2ZyQGDg0SpBf,1,"A substantial number of infected healthcare workers were asymptomatic 28.9%, and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vaccinated against seasonal influenza.",1074,5,5,4,3,2,2,2,2,2,4.666666667,2.333333333,2,"A substantial number of infected healthcare workers were vacciNo Statement hereted (28.9%), and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vacciNo Statement hereted against seasoNo Statement herel influenza.","A minor number of infected healthcare workers were asymptomatic (28.9%), and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vaccinated against seasonal influenza.",55.91,63.15,55.91,10.8,10.4,10.4,7.2,6.5,7.2,11.2,12.49,10.22,8.9,10,8.3,12.56,12.13,12.56,11,12,11,4.3,4.7,4.1,11,12,11,10.8,8.16,9.66,11,10,10,
R_3eb2ZyQGDg0SpBf,1,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.",1080,5,3,4,4,4,4,4,4,4,4,4,4,"Brief, infrequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.","Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of death.",50.16,41.7,58.62,0,0,0,11.5,12.7,10.3,15.03,15.61,13.92,15.8,16.2,14.9,11.45,12.2,10.69,8,8,7,12.5,13.5,11.5,8,8,7,12.21,14.11,10.3,12,13,11,
R_3eb2ZyQGDg0SpBf,1,"The median duration of COVID-19 was shorter in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days). ",1094,4,4,4,2,2,2,2,2,4,4,2,2.666666667,"The median duration of COVID-19 was shorter in the test group compared to the control group (respectively, 11.0 vs 23.0 days).","The median duration of COVID-19 was longer in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days).",69.28,69.28,69.28,0,0,0,6.2,6.2,6.2,10.53,8.56,10.24,9.2,7.6,8.9,14.68,13.93,14.68,7,6,6,5.75,5.75,5.75,7,6,6,9.91,9.91,9.91,6,6,6,
R_3eb2ZyQGDg0SpBf,1,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are common and associated with greater severity of illness.,1150,5,5,4,4,5,4,5,4,4,4.666666667,4.333333333,4.333333333,Early experience with COVID-19 patients suggests that gastrointestiNo Statement herel symptoms are uncommon and associated with greater severity of illness.,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are rare and associated with greater severity of illness.,19.37,8.88,27.83,0,0,0,15,17,13.9,21.11,21.87,20.47,19.5,20.8,19,15.06,15.68,15.06,9,11,8,13,15,13,9,11,8,16.09,18,16.09,15,17,13,
R_3fDAfG4u7BFse4T,0.333333333,"While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",1020,5,1,5,5,5,5,5,5,5,3.666666667,5,5,"While blood testing has been the primary means of diagnosing acute COVID-19 infection, molecular testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.","While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is 100% accurate for diagnosing major infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",10.91,10.91,10.91,0,0,0,22.4,22.4,22.4,17.19,17.19,16.38,27.7,27.7,27.1,13.85,13.85,13.48,16,16,14,32.5,32.5,32.5,16,16,14,26.5,26.5,26.5,0,0,27,
R_3fDAfG4u7BFse4T,0.333333333,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",1027,4,4,4,4,1,4,4,4,4,4,3,4,"Among those with major COVID-19 disease, time to clinical improvement was 9 days in the CBP group, versus 10 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.","Among those with major COVID-19 disease, time to clinical improvement was 14 days in the CBP group, versus 2 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",52.53,60.99,60.99,0,0,0,12.6,11.5,11.5,10.39,10.22,10.22,15,14.8,14.8,10.53,10.24,10.24,13,12,12,17,16.5,16.5,13,12,12,14.5,13.76,13.76,15,12,12,
R_3fDAfG4u7BFse4T,0.333333333,"Migrant worker cases were younger, had few medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia decreased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.",1028,4,3,4,4,4,4,4,4,4,3.666666667,4,4,"Migrant worker cases were younger, had no medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia increased, whilst patients presenting earlier in their illness and asymptomatic disease became less common.","Migrant worker cases were older, had a lot of medical comorbidities and less very disease. As the migrant worker cases decreased, the proportion of patients with pneumonia increased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.",34.76,34.76,33.75,0,0,0,13.3,13.3,13.6,17.69,17.52,15.84,17.3,17.2,16.3,11.89,11.49,11.2,16,15,16,13.25,13.25,13.75,16,15,16,14.98,14.98,15.03,12,18,14,
R_3fDAfG4u7BFse4T,0.333333333,"A substantial number of infected healthcare workers were asymptomatic 28.9%, and 35.5% were admitted to hospital. The mean length of hospital stay was 8.1 days. 70.1% of confirmed cases had been vaccinated against seasonal influenza.",1074,4,4,4,4,5,4,4,4,4,4,4.333333333,4,"A substantial number of infected healthcare workers were asymptomatic (45.6%), and 51.2% were admitted to hospital. The mean length of hospital stay was 11.4 days. 70.1% of confirmed cases had been vacciNo Statement hereted against seasoNo Statement herel influenza.","A substantial number of infected healthcare workers were asymptomatic (78%), and 10% weren't admitted to hospital. The mean length of hospital stay was 18 days. 90% of confirmed cases had been vaccinated against seasonal influenza.",55.91,63.56,51.14,10.8,10.4,13,7.2,6.3,9,11.2,12.31,12.51,8.9,10,10.9,12.56,13.34,11.89,11,13,12,4.3,4.5,7.833333333,11,13,12,10.8,9.27,12.68,11,10,13,
R_3fDAfG4u7BFse4T,0.333333333,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.",1080,5,4,4,5,4,4,4,4,4,4.333333333,4.333333333,4,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with minimal risk of infection.","Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with no risk of infection.",50.16,42.72,51.18,0,0,0,11.5,12.3,11.1,15.03,15.49,14.04,15.8,15.7,14.5,11.45,11.73,10.94,8,8,7,12.5,13,12,8,8,7,12.21,14,12,12,12,12,
R_3iwokv3dX2q4nIL,0,"While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",1020,3,3,3,2,4,2,3,3,3,3,2.666666667,3,"While molecular testing has been the secondary means of diagnosing acute COVID-19 infection, blood testing is gaining importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.","While molecular testing has been the primary means of diagnosing acute COVID-19 infection, blood testing is losing importance for diagnosing minor infections or supporting the diagnosis of difficulty breathing in cases where the pathogen is no longer detectable in the upper respiratory tract.",10.91,10.91,10.91,0,0,0,22.4,22.4,22.4,17.19,17.48,17.07,27.7,27.9,27.6,13.85,13.85,13.85,16,16,16,32.5,31.5,32.5,16,16,16,26.5,25.57,26.5,0,0,0,
R_3iwokv3dX2q4nIL,0,"Migrant worker cases were younger, had few medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia decreased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.",1028,4,2,5,4,1,4,3,5,4,3.666666667,3,4,"Migrant worker cases were older, had few medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia decreased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.","Migrant worker cases were older, younger, and equal, while had few medical comorbidities and less severe disease. As the migrant worker cases increased, the proportion of patients with pneumonia decreased, whilst patients presenting earlier in their illness and asymptomatic disease became more common.",34.76,34.76,41.19,0,0,0,13.3,13.3,12.9,17.69,17.35,16.82,17.3,17.1,17.8,11.89,11.89,11.68,16,17,17,13.25,13.25,14.25,16,17,17,14.98,14.98,15.11,12,12,13,
R_3iwokv3dX2q4nIL,0,"150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",1031,3,2,4,3,3,3,4,4,4,3,3,4,"140 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 35% of favipiravir and 8% of control patients.","1 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",61.67,60.65,60.65,11.2,11.2,11.2,9.1,9.5,9.5,10.15,9.57,9.4,10.8,10.5,10.4,10.67,10.4,10.4,13,13,13,11,11.5,11.5,13,13,13,10.9,11.11,11.11,11,10,10,
R_3iwokv3dX2q4nIL,0,"When each vitamin D status group was considered, 69.44% of the vitamin D deficient group had severe COVID-19 and 81.82% of the severely deficient group had severe COVID-19.",1151,4,2,4,5,1,4,4,5,4,3.333333333,3.333333333,4.333333333,70% of the vitamin D deficient group had severe COVID-19 and 82.3% of the severely deficient group had sever COVID-19.,0% of the vitamin D deficient group had severe COVID-19 and 3% of the severely deficient group had sever COVID-19.,70.5,69.79,59.64,11.2,0,0,5.7,6,9.9,9.31,8.21,8.82,7.6,6.9,10.9,11.43,12.82,12.52,6,5,5,5.666666667,6,14,6,5,5,9.43,10,14,6,6,14,
R_3iwokv3dX2q4nIL,0,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,1154,4,1,5,3,3,4,4,4,4,3.333333333,3.333333333,4,Weight gain was present in 85% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,Weight gain was present in 0% and weight loss in 0% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,68.47,68.47,68.47,9.7,9.7,9.7,6.5,6.5,6.5,13.61,13.61,13.26,11.3,11.3,11,10.23,10.23,9.77,7,7,7,6,6,6,7,7,7,9.23,9.23,9.23,10,10,10,
R_3JLdTJJ3ZPHboyt,0,"Global influenza virus spread decreased during the COVID-19 pandemic, possibly due to widespread community mitigation measures.",1011,4,4,5,4,4,4,5,4,3,4.333333333,4,4,"Global influenza virus spread decreased during the COVID-19 pandemic, possibly due to less travel due to travel bans.","Global influenza virus spread decreased during the COVID-19 pandemic, possibly due to vaccinations.",12.94,53.21,32.9,0,0,0,15.4,10.3,11.9,21.92,13.69,19.3,19.5,13.8,16.6,16.27,13.3,15.21,9,6,6,13,12,10.5,9,6,6,18.9,13.87,17.51,13,14,12,
R_3JLdTJJ3ZPHboyt,0,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of early identification of asymptomatic carriers.",1014,4,3,5,5,4,5,5,5,5,4,4.666666667,5,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were unvacciNo Statement hereted and asymptomatic, while 25% of vacciNo Statement hereted positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of No Statement heretural immunity in patients.","We evaluated 298 persons and identified twelve positive cases. 83.7% of the positive cases were asymptomatic, while only 26.3% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of early identification of asymptomatic carriers",32.19,29.86,35.64,15,15.5,13.4,12.2,13.1,10.8,15.25,16.01,14.65,13.2,14.6,11.9,11.25,12,11.85,15,19,15,11.16666667,12.66666667,7.375,15,19,15,15.24,16.4,13.88,12,13,12,
R_3JLdTJJ3ZPHboyt,0,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as a therapeutic target for COVID-19.",1016,5,4,5,3,2,2,2,2,2,4.666666667,2.333333333,2,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cell replacement as a therapeutic alterNo Statement heretive for COVID-19.","Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as a homeopathic target for COVID-19.",58.28,48.3,58.28,0,0,0,8.4,10.1,8.4,12.63,15.3,12.63,11.4,13.9,11.4,12.18,12.52,12.18,9,12,9,7.5,10.25,7.5,9,12,9,11.35,14.08,11.35,8,11,8,
R_3JLdTJJ3ZPHboyt,0,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19.  This suggests that chilblains might be a symptom of COVID-19.,1017,4,4,4,5,5,5,5,5,5,4,5,5,Microscopic abnormalities have been observed in both finger and toeNo Statement hereils of vacciNo Statement hereted patients with breakthrough COVID-19 infections. This suggests that chilblains might be a symptom of weakened immunity.,Microscopic abnormalities have been observed in both finger and toenails of vaccinated patients with breakthrough COVID-19 infections. This suggests that chilblains might be caused by the COVID-19 vaccination.,67.76,46.78,40.35,0,0,0,6.8,10.7,11.1,14.2,18.85,19.02,11.7,16.6,16.2,10.81,13.31,12.23,7,12,10,6,10.5,8.5,7,12,10,8.13,12.65,12.74,7,11,13,
R_3JLdTJJ3ZPHboyt,0,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, and evidence of confirmed cases in the neighbourhood could help discriminate infected patients from uninfected.",1018,3,2,4,5,4,5,5,5,5,3,4.666666667,5,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, state vacciNo Statement heretion rates, and evidence of confirmed cases in the neighborhood could help discrimiNo Statement herete infected patients from uninfected.","We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster,  and evidence of unconfirmed cases in the neighborhood could help discriminate infected patients from uninfected.",24.11,17.01,24.11,0,0,0,23.6,26.3,23.6,13.65,14.58,13.77,32.2,36.3,32.3,12.68,13.33,12.39,17,19,16,33.5,38,34.5,17,19,16,25.64,28.03,25.64,13,13,24,
R_3kcfgjrtleFZ8cQ,0.666666667,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",1027,4,4,4,4,4,4,4,4,4,4,4,4,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.","Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",52.53,52.53,52.53,0,0,0,12.6,12.6,12.6,10.39,10.39,10.39,15,15,15,10.53,10.53,10.53,13,13,13,17,17,17,13,13,13,14.5,14.5,14.5,15,15,15,
R_3kcfgjrtleFZ8cQ,0.666666667,"150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",1031,4,4,4,4,4,4,4,4,4,4,4,4,"150 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.","150 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",61.67,60.65,60.65,11.2,11.2,11.2,9.1,9.5,9.5,10.15,9.57,9.57,10.8,10.5,10.5,10.67,10.4,10.4,13,13,13,11,11.5,11.5,13,13,13,10.9,11.11,11.11,11,10,10,
R_3kcfgjrtleFZ8cQ,0.666666667,Children with serious underlying medical conditions had a 1.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 2.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 2.81 times higher risk of death from COVID-19 compared to healthy children.,1088,4,4,4,4,4,4,4,4,4,4,4,4,Children with serious underlying medical conditions had a 3.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 1.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 281 times higher risk of death from COVID-19 compared to healthy children.,Children with genuine fundamental therapeutic conditions had a 1.79 times higher chance of extreme COVID-19 than for solid children. Children with corpulence were found to be 2.87 times more likely to urge extreme COVID-19 than solid children. Children with fundamental conditions moreover had a 2.81 times higher chance of passing from COVID-19 compared to sound children.,70.5,68.57,62.04,9.3,9.9,8.8,5.7,6.5,6.9,11.28,11.87,12.96,8.6,9.5,10,8.89,8.99,9.74,8,8,11,4.833333333,6,4.666666667,8,8,11,7.29,8.05,6.58,9,9,7,
R_3kcfgjrtleFZ8cQ,0.666666667,Patients hospitalized and in the ICU because of COVID-19 have a higher metabolism and require more calories than their non-COVID counterparts.,1153,2,2,3,4,4,4,4,4,4,2.333333333,4,4,Patients hospitalized and in the ICU because of COVID-19 have a lower metabolism and require less calories than their non-COVID counterparts.,Patients hospitalized and in the ICU because of COVID-19 have the same metabolism and require the same amount of calories as their non-COVID counterparts.,41.7,41.7,55.58,0,0,0,12.7,12.7,11.5,15.61,15.32,13.93,16.4,16.2,16.3,12.95,12.95,11.41,7,7,6,13.5,13.5,15,7,7,6,14.11,14.11,14.6,13,13,15,
R_3kcfgjrtleFZ8cQ,0.666666667,Weight gain was present in 87% and weight loss in 13% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,1154,2,2,4,4,4,4,4,4,4,2.666666667,4,4,Weight gain was present in 60% and weight loss in 25% of patients hospitalized with COVID-19. Most patients present excess body weight according to body mass index. Covid-19 patients recovered their weight after hospitalization.,Weight gain was present in 13% and weight loss in 87% of patients hospitalized with COVID-19. Most patients present less body weight according to body mass index. Covid-19 patients never recovered their weight after hospitalization.,68.47,68.47,68.06,9.7,9.7,9.7,6.5,6.5,6.7,13.61,13.61,13.2,11.3,11.3,11.1,10.23,10.23,9.63,7,7,6,6,6,6.166666667,7,7,6,9.23,9.23,9.25,10,10,10,
R_3kdJOQB6PDffmnm,0,"Global influenza virus spread decreased during the COVID-19 pandemic, possibly due to widespread community mitigation measures.",1011,1,2,3,3,4,3,3,3,4,2,3.333333333,3.333333333,"Global influenza virus spread decreased during the black plague pandemic, possibly due to widespread community mitigation measures.","Global influenza virus spread increased during the COVID-19 pandemic, possibly due to non-widespread community mitigation measures.",12.94,20.38,12.94,0,0,0,15.4,14.6,15.4,21.92,20.99,23.02,19.5,18.9,20.7,16.27,14.7,17.26,9,9,9,13,13.5,13,9,9,9,18.9,18.56,18.9,13,15,13,
R_3kdJOQB6PDffmnm,0,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of early identification of asymptomatic carriers.",1014,4,4,3,5,5,4,4,4,4,3.666666667,4.666666667,4,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included headaches, vomiting, and pain. Our data confirm the importance of early identification of asymptomatic carriers.","We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the non-importance of early identification of asymptomatic carriers.",32.19,32.19,23.73,15,15,15,12.2,12.2,13.4,15.25,15.65,15.65,13.2,13.6,13.7,11.25,11.63,11.63,15,15,15,11.16666667,11.16666667,11.16666667,15,15,15,15.24,15.24,15.24,12,12,14,
R_3lsK23ycTr8gqHT,1,"COVID-19 patients with recurrent epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.",1019,4,4,4,2,2,2,3,3,2,4,2,2.666666667,"COVID-19 patients with recurrent epileptic seizures had about the same number of underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.","COVID-19 patients without epileptic seizures had more underlying neurological diseases than patients who had an epilepsy history but without a seizure. Patients with new-onset and recurrent epileptic seizures suffered more severe/critical COVID-19, which may lead to a worse prognosis.",42.72,40.69,43.22,0,0,0,12.3,13.1,12.1,18.39,17.23,18.39,18.4,18.3,18.1,10.94,10.47,11.08,12,12,12,13.5,14.5,12.75,12,12,12,13,13.35,12.93,13,13,13,
R_3lsK23ycTr8gqHT,1,"150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",1031,4,4,4,3,3,3,3,3,3,4,3,3,"150 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 6.36 days versus 7.03 days, and median time to clinical cure was 4.58 days versus 5.11 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 1% of control patients.","150 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 1 days versus 7 days, and median time to clinical cure was immediate versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",61.67,71.71,60.95,11.2,8.4,11.9,9.1,5.3,9.4,10.15,8.31,10.5,10.8,6.1,11.1,10.67,10.96,10.77,13,13,14,11,3.928571429,11.66666667,13,13,14,10.9,6.75,11.77,11,7,12,
R_3lsK23ycTr8gqHT,1,Children with serious underlying medical conditions had a 1.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 2.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 2.81 times higher risk of death from COVID-19 compared to healthy children.,1088,4,4,4,4,4,4,4,4,4,4,4,4,Children with serious underlying medical conditions had a 1.01 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 1.17 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 1.21 times higher risk of death from COVID-19 compared to healthy children.,Children with serious underlying medical conditions had a 11.79 times higher risk of severe COVID-19 than for healthy children. Children with obesity were found to be 3212.87 times more likely to get severe COVID-19 than healthy children. Children with underlying conditions also had a 23234.81 times higher risk of death from COVID-19 compared to healthy children.,70.5,70.5,70.5,9.3,9.3,9.3,5.7,5.7,5.7,11.28,11.28,12.15,8.6,8.6,9.3,8.89,8.61,9.17,8,8,8,4.833333333,4.833333333,4.833333333,8,8,8,7.29,7.29,7.29,9,9,9,
R_3lsK23ycTr8gqHT,1,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects. ",1090,4,4,4,4,4,4,4,4,4,4,4,4,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 but more likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects.","There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although severe side effects were found",57.61,57.61,60.14,0,0,0,10.7,10.7,9.7,12.01,12.01,12.59,14.2,14.2,13.3,11.55,11.55,11.89,11,11,11,14,14,11.75,11,11,11,13.35,13.35,11.9,14,14,12,
R_3lsK23ycTr8gqHT,1,"The COVID-19 epidemic could be controlled by alternating one or two weeks of complete lockdown with one or two months of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coronavirus impact on economy.",1180,4,4,4,4,4,4,4,4,4,4,4,4,"The COVID-19 epidemic could be controlled by alterNo Statement hereting one or two weeks of complete lockdown with one or two weeks of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coroNo Statement herevirus impact on economy.","The COVID-19 epidemic could be controlled by alternating one or two months of complete lockdown with one or two days of freedom, respectively. Control strategies of this kind, where the lockdowns duration is well circumscribed, could be important also to alleviate coronavirus impact on economy.",40.18,46.61,40.18,0,0,0,13.2,12.8,13.2,14.74,15.09,14.57,16.3,17.5,16.2,11.42,11.62,11.42,14,16,14,15.75,16.25,15.75,14,16,14,16.11,15.51,16.11,16,16,16,
R_3Q7rRZIwDG0wpY5,1,A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.,1006,5,5,5,5,5,5,5,5,5,5,5,5,The WHO have investigated that A 5-day course of ivermectin was found to be dangerous and ineffective in treating adult patients with mild COVID-19.,A 5-day course of ivermectin was found to be relatively safe and effective in treating adult patients with mild COVID-19.,77.57,55.58,68.1,0,0,0,7.2,11.5,8.7,9.86,12.48,11.43,10.9,15.1,12.6,12.06,11.41,12.52,4,5,5,10.5,15,12,4,5,5,9.71,12.93,12,10,12,12,
R_3Q7rRZIwDG0wpY5,1,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.",1010,1,1,4,4,4,4,4,4,4,2,4,4,"The World Health Organization has reached a consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally several days depending on symptoms, after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.","We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to Covid-19. Antibody tests for high affinity antibodies should be performed ideally after potential infectious contact, given that most exposed individuals should have begun to produce antibodies by then.",17.17,13.62,9.72,0,0,0,17.9,19.3,18.7,17.12,17.3,17.82,21,22.7,21,12.53,12.13,11.89,19,21,19,22.25,25,21.75,19,21,19,19.82,20.93,19.73,18,13,19,
R_3Q7rRZIwDG0wpY5,1,"Global influenza virus spread decreased during the COVID-19 pandemic, possibly due to widespread community mitigation measures.",1011,5,5,5,5,5,5,5,5,5,5,5,5,"Global influenza virus spread increase during the COVID-19 pandemic, possibly due to lack of participation in community mitigation measures.","Global influenza virus spread increase during the COVID-19 pandemic, possibly due to lack of community mitigation measures.",12.94,9.89,28.84,0,0,0,15.4,16.6,13.5,21.92,19.03,17.92,19.5,18.3,16.7,16.27,15.38,15.63,9,9,8,13,15.5,13.5,9,9,8,18.9,20.23,18.56,13,16,14,
R_3Q7rRZIwDG0wpY5,1,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1013,2,2,2,5,5,5,5,5,5,2,5,5,A need for mechanical ventilation occurred in 65% of the aNo Statement herekinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the aNo Statement herekinra-treated group compared with 27% of the control group.,A need for mechanical ventilation occurred in most of the anakinra-treated group and almost all of the control group. Successful weaning from supplemental oxygen was attained in a large portion of the anakinra-treated group compared with a small percent of the control group.,52.19,41.7,49.65,0,0,0,10.7,12.7,11.7,12.94,13.63,13.63,13.6,15.1,14.8,11.23,11.45,9.84,12,13,14,12.5,13.5,13.75,12,13,14,11.81,13.16,12.32,13,14,14,
R_3Q7rRZIwDG0wpY5,1,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19.  This suggests that chilblains might be a symptom of COVID-19.,1017,3,3,3,5,5,5,5,5,5,3,5,5,Abnormalities have been observed in both index fingers and Hallux toes of patients with COVID-19. This suggests that inflammation of the hands or feet might be a symptom of COVID-19.,Tiny abnormalities have been observed in both the hands and feet of patients with COVID-19. This suggests that swollen feet  might be a symptom of COVID-19.,67.76,64.71,83.66,0,0,0,6.8,8,4.8,14.2,10.95,9.96,11.7,10.1,8.6,10.81,11.22,9.75,7,9,5,6,7.5,6,7,9,5,8.13,8.67,6.74,7,8,10,
R_3qCJFCtx8Z7IlWF,0,"While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalised patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of non-hospitalised patients. Antibody levels were initially low, increased over time, and increased as the disease got worse. ",1024,4,4,4,4,4,4,4,4,4,4,4,4,"While Test A failed to detect SARS-CoV-2 antibodies in 3784% of non-hospitalized patients, Test B detected antibodies in 79%. Test C detected antibodies in 95% of non-hospitalized patients. Antibody levels were initially low, increased over time, and increased as the disease got worse.","While Test A failed to detect SARS antibodies in non-hospitalized patients, Test B detected antibodies in most . Test C detected antibodies in 95% of non-hospitalized patients. Antibody levels were initially low, increased over time, and increased as the disease got worse.",48.5,48.5,40.65,13,13,13,10,10,11,13.27,13.27,13.68,12.6,12.6,12.1,12.06,12.06,10.48,10,10,10,10.16666667,10.16666667,9,10,10,10,10.37,10.37,10.36,13,13,11,
R_3qCJFCtx8Z7IlWF,0,"Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.",1027,4,4,4,4,4,4,4,4,4,4,4,4,"Among those with severe COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with an unfavorable outcome in the rate of, and time to, clinical improvement.","Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a dangerous treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical decline.",52.53,52.53,52.53,0,0,0,12.6,12.6,12.6,10.39,10.51,10.51,15,15.1,15.1,10.53,10.53,10.82,13,13,14,17,16.5,17,13,13,14,14.5,13.76,14.5,15,11,11,
R_3qCJFCtx8Z7IlWF,0,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects. ",1090,4,4,4,4,2,4,2,2,2,4,3.333333333,2,"There appears to be an age gradient, with younger children seemingly more susceptible to SARS-CoV-2 and more likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects.","There appears to be an age gradient, with younger children seemingly more susceptible to SARS-CoV-2 and more likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was able to identify all side-effects that were deadly.",57.61,57.61,57.1,0,0,0,10.7,10.7,10.9,12.01,12.01,12.42,14.2,14.2,14.5,11.55,11.55,11.42,11,11,12,14,14,14.25,11,11,12,13.35,13.35,13.44,14,14,11,
R_3qCJFCtx8Z7IlWF,0,Early nutritional screening is therefore an important step in order to perform an adequate nutritional intervention as part of COVID-19 management.,1152,4,4,4,4,4,4,4,4,4,4,4,4,Developmental nutritioNo Statement herel screening is therefore an important step in order to perform an adequate nutritioNo Statement herel intervention as part of COVID-19 maNo Statement heregement.,Nutritional screening is therefore an not required step in order to perform an adequate nutritional intervention as part of COVID-19 management,16.32,18.69,24.78,0,0,0,16.2,17.4,15,17.23,19.96,16.42,17.6,22.4,16.7,11.45,12.58,12.2,7,10,8,16.5,19.5,15.5,7,10,8,16.02,16.73,16.02,17,20,16,
R_3qCJFCtx8Z7IlWF,0,"Compared to White respondents, American Indian/Alaska Native and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being extremely likely to be vaccinated.",1164,4,4,4,4,4,4,4,4,4,4,4,4,"Compared to White respondents, American Indian/Alaska No Statement heretive and Black/African American respondents were more likely, and Asian and Spanish-speaking Latino respondents were less likely to report being extremely likely to be vacciNo Statement hereted.","Compared to Asian and Spanish-speaking Latino respondents, American Indian/Alaska Native and Black/African American respondents were more likely, and white respondents were more likely to report being extremely unlikely to be vaccinated.",6.17,10.57,6.17,0,0,0,20.1,20.5,20.1,20.55,20.61,20.9,25.2,27.2,25.5,10.78,11.24,11.29,9,10,10,24.5,26.5,25.5,9,10,10,16.27,17.43,17.56,21,21,26,
R_3qfJOOLPucdJoGd,0.333333333,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells. ,1005,4,4,4,4,4,4,4,4,4,4,4,4,Intravenous recombiNo Statement herent ACE2 was announced as an effective therapy in severe COVID-19 by blocking the viral entry to target cells.,Intravenous recombinant ACE2 was reported as a cure in severe COVID-19 by blocking the viral entry to target cells.,34.26,32.22,52.19,0,0,0,13.5,14.2,10.7,14.04,14.91,11.72,14.5,16.1,12.1,15.68,16.21,14.55,10,12,8,15,15,12.5,10,12,8,18,16.07,13.92,15,15,12,
R_3qfJOOLPucdJoGd,0.333333333,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.",1010,2,3,4,4,3,4,4,4,4,3,3.666666667,4,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should always be performed 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.","We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should always be performed within 21 days after potential infectious contact, given that most exposed individuals always produce antibodies by then.",17.17,17.17,9.72,0,0,0,17.9,17.9,18.7,17.12,17,17.93,21,20.9,21.2,12.53,12.25,12.75,19,18,19,22.25,21.75,21.25,19,18,19,19.82,19.12,19,18,18,19,
R_3qfJOOLPucdJoGd,0.333333333,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1013,5,2,2,1,1,1,1,1,1,3,1,1,A need for ventilation occurred in 31% of the aNo Statement herekinra-treated group and 75% of the control group. Successful weaning from air was attained in 63% of the aNo Statement herekinra-treated group compared with 27% of the control group.,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Unsuccessful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,52.19,59.64,43.73,0,0,0,10.7,9.9,11.9,12.94,11.55,13.23,13.6,13,13.8,11.23,10.55,11.23,12,10,12,12.5,12,12.5,12,10,12,11.81,11,11.81,13,12,12,
R_3qfJOOLPucdJoGd,0.333333333,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19.  This suggests that chilblains might be a symptom of COVID-19.,1017,4,4,4,4,4,4,4,4,4,4,4,4,Microscopic abnormalities have been observed in both finger and toeNo Statement hereils of patients with COVID-19. This suggests that chilblains is a symptom of COVID-19.,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19. This suggests that chilblains is a sure sign of COVID-19.,67.76,67.25,67.76,0,0,0,6.8,7,6.8,14.2,14.78,13.27,11.7,12.3,10.9,10.81,11.84,10.15,7,7,6,6,6.25,6,7,7,6,8.13,8.2,8.13,7,7,11,
R_3qfJOOLPucdJoGd,0.333333333,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, and evidence of confirmed cases in the neighbourhood could help discriminate infected patients from uninfected.",1018,4,4,4,4,4,3,4,4,4,4,3.666666667,4,"We found that age, symptom onset between 3 and 14 days, flu, common cold, and evidence of confirmed cases in the neighborhood could help discrimiNo Statement herete infected patients from uninfected.","We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, and evidence of confirmed cases in the country could help discriminate infected patients from uninfected.",24.11,40.01,24.11,0,0,0,23.6,15.4,23.6,13.65,13.99,13.01,32.2,19.7,31.7,12.68,13.32,12.39,17,11,16,33.5,20.5,32.5,17,11,16,25.64,17.56,24.91,13,14,13,
R_3rPx5Bcrq1DbWx6,0,"150 patients were randomized to favipiravir or the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.",1031,4,2,2,4,4,4,4,4,4,2.666666667,4,4,"150 patients were selected to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients.","150 patients were randomized to be on favipiravir or in the control group. Median time to the cessation of viral shedding was 5 days versus 7 days, and median time to clinical cure was 3 days versus 5 days ,for favipiravir and control, respectively. Aiding events were observed in 36% of favipiravir and 8% of control patients.",61.67,60.65,60.65,11.2,11.2,11.2,9.1,9.5,9.5,10.15,9.4,9.46,10.8,10.4,10.4,10.67,10.4,10.4,13,13,13,11,11.5,11.5,13,13,13,10.9,11.11,11.11,11,10,10,
R_3rPx5Bcrq1DbWx6,0,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are common and associated with greater severity of illness.,1150,3,3,4,4,4,4,4,4,4,3.333333333,4,4,Early surveys with COVID-19 patients suggests that gastrointestiNo Statement herel symptoms are common and associated with greater severity of illness.,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are abnormal and associated with greater severity of illness.,19.37,25.8,10.91,0,0,0,15,14.6,16.2,21.11,20.42,21.75,19.5,19.7,20,15.06,15.68,15.06,9,11,9,13,13,14,9,11,9,16.09,14,18.31,15,13,16,
R_3rPx5Bcrq1DbWx6,0,Early nutritional screening is therefore an important step in order to perform an adequate nutritional intervention as part of COVID-19 management.,1152,4,2,4,4,2,4,4,4,4,3.333333333,3.333333333,4,Starting nutritioNo Statement herel screening is therefore an important step in order to perform an adequate nutritioNo Statement herel intervention as part of COVID-19 maNo Statement heregement.,Early nutritional diet is therefore an important step in order to perform an adequate nutritional intervention as part of COVID-19 management.,16.32,27.15,16.32,0,0,0,16.2,16.2,16.2,17.23,18.92,15.84,17.6,21.6,16.4,11.45,12.58,11.45,7,10,7,16.5,18.5,16.5,7,10,7,16.02,15.24,16.02,17,19,16,
R_3rPx5Bcrq1DbWx6,0,"Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",1160,4,2,3,2,2,3,3,2,2,3,2.333333333,2.333333333,"Of all the patients, 9.1% required admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen. admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, some changes in results were seen.","Of all the patients, 9.1% requesting admission to the intensive care unit (ICU), of whom 83% died. The average length of ICU stay was 11 days. The observed mortality rates in blood groups A, B, AB and 0 were 86.4%, 93.3%, 80.0% and 70.8%, respectively, indicating similar death rates in all ABO blood types. When the Rh phenotype was taken into consideration, no significant changes in results were seen.",69.89,69.68,69.89,10,10,10.3,6,6,6,7.11,6.99,7.28,6.3,6.3,6.4,12.59,8.6,12.59,14,14,14,5.357142857,5.4,5.5,14,14,14,9.76,7.09,10.34,6,6,6,
R_3rPx5Bcrq1DbWx6,0,"Compared to White respondents, American Indian/Alaska Native and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being extremely likely to be vaccinated.",1164,2,2,2,4,4,4,4,4,4,2,4,4,"Compared to White respondents, American Indian/Alaska No Statement heretive and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being extremely likely to be tested for COVID-19.","Compared to White respondents, American Indian/Alaska Native and Black/African American respondents were less likely, and Asian and Spanish-speaking Latino respondents were more likely to report being somewhat likely to be vaccinated.",6.17,10.57,6.17,0,0,0,20.1,20.5,20.1,20.55,19.45,20.37,25.2,26.4,25.1,10.78,11.69,10.78,9,10,9,24.5,25.5,23.5,9,10,9,16.27,16.29,14.98,21,26,20,
R_6St6oY4L7rJl917,0,"Close, frequent contact with patients and those exposed to patients with cough symptoms are associated with an increased risk of infection.",1080,4,4,4,4,4,4,4,4,4,4,4,4,There is a greater risk of infection if there is close and frequent contact with patients with a cough.,Wash your hands after coming into contact with a patient with a cough and you lessen the risk of infection.,50.16,77.57,68.1,0,0,0,11.5,7.2,8.7,15.03,8.36,7.95,15.8,9.1,9.3,11.45,9.57,9.37,8,4,3,12.5,10.5,11,8,4,3,12.21,9.71,10,12,10,9,
R_6St6oY4L7rJl917,0,"There appears to be an age gradient, with younger children seemingly less susceptible to SARS-CoV-2 and less likely to pass it on. The BNT162b2 vaccine appeared well tolerated in children aged 1215 years, although the study was too small to identify any rare side-effects. ",1090,4,4,4,4,4,4,4,4,4,4,4,4,"Younger children are less likely to get SARS-CoV-2 and pass it on. The BNT163b2 vaccine are well tolerated in children ages 12-15, even though the study is too small to identify and rare side-effects.","Age matters because kids can't catch SARS-CoV-2 and aren't carriers. The vaccine it also proven to adjust well in children, though the study was small and couldn't identify side effects.",57.61,71.14,73.17,0,0,0,10.7,7.6,6.8,12.01,9.74,10.95,14.2,10.2,10.7,11.55,10.52,10.17,11,5,6,14,9,7.5,11,5,6,13.35,9.15,8.67,14,10,11,
R_6St6oY4L7rJl917,0,Early experience with COVID-19 patients suggests that gastrointestinal symptoms are common and associated with greater severity of illness.,1150,3,3,4,4,4,4,4,4,4,3.333333333,4,4,"Early symptoms of COVID-19, like gastrointestiNo Statement herel symptoms, are common and are often associated with greater severity of illness.","Gastric bypass patients who displayed early symptoms of COVID-19, are common and often associated with severe illness.",19.37,25.8,37.3,0,0,0,15,14.6,12.3,21.11,17.81,16.18,19.5,18,15.3,15.06,13.31,14.7,9,8,9,13,13,8.5,9,8,9,16.09,14,9.15,15,13,15,
R_6St6oY4L7rJl917,0,"When each vitamin D status group was considered, 69.44% of the vitamin D deficient group had severe COVID-19 and 81.82% of the severely deficient group had severe COVID-19.",1151,2,2,2,2,2,2,2,2,2,2,2,2,"Of the patients admitted to the hospital with severe COVID-19, 64.44% were vitamin D deficient and 81.82% of the severely deficient group had severe COVID-19.","Vitamin D deficient people have a greater chance of having severe COVID-19. In a survey, 69.44% of patients that had COVID-19 were vitamin d deficient and 81.82% of that percentage had severe COVID-19.",70.5,63.05,71.51,11.2,11.2,9.5,5.7,6.5,5.3,9.31,9.88,8.6,7.6,8,6.8,11.43,12.26,10.75,6,6,6,5.666666667,5.166666667,4.375,6,6,6,9.43,9.72,6.96,6,10,7,
R_6St6oY4L7rJl917,0,Patients hospitalized and in the ICU because of COVID-19 have a higher metabolism and require more calories than their non-COVID counterparts.,1153,4,3,4,4,4,4,5,4,4,3.666666667,4,4.333333333,"Patients that are hospitalized because of COVID-19, tend to have a higher metabolism than those who do not, and require more food than.","Patients who are hospitalized because of COVID-19, are usually more petite than those who aren't and because of this, they need way more food than those without COVID-19 and have a fast metabolism because of COVID-19",41.7,65.05,51.86,0,0,0,12.7,9.9,15,15.61,10.51,11.5,16.4,13.2,20.3,12.95,10.27,8.49,7,5,5,13.5,13.5,21,7,5,5,14.11,12.68,17.73,13,10,21,
R_bNP12x4Wyamgo81,0,A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.,1006,4,4,4,3,4,4,4,4,4,4,3.666666667,4,A 5-day course of ivermectin was found to be safe and effective in treating adult patients with non deathlike or deathlike COVID-19.,A 5-day course of ivermectin was found to be perfectly safe without any symptoms for sure in treating adult patients with mild COVID-19.,77.57,74.53,73.51,0,0,0,7.2,8.3,8.7,9.86,11.2,11.03,10.9,13.4,13.4,12.06,11.9,11.64,4,5,5,10.5,12,12.5,4,5,5,9.71,10.62,10.94,10,12,11,
R_bNP12x4Wyamgo81,0,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.",1010,2,2,2,2,2,2,2,2,2,2,2,2,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.","Testing algorithms can now be used to test antibodies for asymptomatic subjects exposed to SARS-CoV-2. They should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.",17.17,17.17,34.76,0,0,0,17.9,17.9,13.3,17.12,17.12,15.32,21,21,15.4,12.53,12.53,11.89,19,19,13,22.25,22.25,13.75,19,19,13,19.82,19.82,14.98,18,18,15,
R_bNP12x4Wyamgo81,0,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as a therapeutic target for COVID-19.",1016,4,4,4,4,4,4,4,4,4,4,4,4,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as a high unmet medical need for COVID-19.","Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results show that COVID-19 targets white blood cells.",58.28,65.73,68.26,0,0,0,8.4,7.6,6.6,12.63,11.36,12.04,11.4,10.5,10.6,12.18,11.66,11.76,9,9,7,7.5,8,5.75,9,9,7,11.35,11.31,8.08,8,8,12,
R_RQXhfkx99zwO8XT,0,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells. ,1005,3,3,2,3,3,3,3,2,4,2.666666667,3,3,Intravenous recombiNo Statement herent ACE2 was reported as an ineffective therapy in severe COVID-19 because it didn't successfully block the viral entry of the cells targeted.,Intravenous recombinant ACE2 was reported as an ineffective therapy in severe COVID-19 by blocking the viral entry to target cells.,34.26,19.71,25.8,0,0,0,13.5,17,14.6,14.04,16.25,14.62,14.5,19.1,14.9,15.68,14.64,15.68,10,12,10,15,20,15,10,12,10,18,21.17,18,15,17,15,
R_RQXhfkx99zwO8XT,0,A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19.,1006,4,4,4,4,4,4,4,4,4,4,4,4,A5-day course of ivermectin was found to be unsafe and ineffective in treating adult patients with mild COVID-19.,A 5-day course of ivermectin was found to be unsafe and effective in treating adult patients with mild COVID-19.,77.57,70.13,77.57,0,0,0,7.2,8,7.2,9.86,12.41,10.5,10.9,12.7,11.4,12.06,13.3,12.89,4,5,5,10.5,9,10.5,4,5,5,9.71,9.42,9.71,10,13,11,
R_RQXhfkx99zwO8XT,0,"We reached consensus on the applicability of diagnostic tools to provide testing algorithms for the use of antibody tests of high-affinity antibodies for asymptomatic subjects exposed to SARS-CoV-2. Antibody tests for high affinity antibodies should be performed ideally 21 days after potential infectious contact, given that most exposed individuals will have begun to produce antibodies by then.",1010,2,2,2,2,2,2,2,2,2,2,2,2,"Antibody tests for high affinity antibodies should be performed ideally 21 days before potential infectious contact, given that most exposed individuals haven't begun to produce antibodies by then.","Antibody tests for high affinity antibodies should be performed ideally 21 days before potential infectious contact, given that most exposed individuals haven't begun to produce antibodies by then.",17.17,9.22,9.22,0,0,0,17.9,18.9,18.9,17.12,17.58,17.58,21,21.2,21.2,12.53,12.92,12.92,19,11,11,22.25,22,22,19,11,11,19.82,21.2,21.2,18,22,22,
R_RQXhfkx99zwO8XT,0,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1013,2,2,2,3,3,3,3,3,3,2,3,3,Being fully dependable on supplemental oxygen was attained at 63% of the aNo Statement herekinra-treated group compared with 27% of the control group.,Unsuccessful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,52.19,39.67,42.72,0,0,0,10.7,13.4,12.3,12.94,14.28,15.2,13.6,16.3,15.9,11.23,13.02,13.31,12,9,9,12.5,14.5,13,12,9,9,11.81,14.42,12,13,14,13,
R_RQXhfkx99zwO8XT,0,"Over the 14-day study period, six patients survived, two were extubated, and one discharged. The results implicate white blood cells as a therapeutic target for COVID-19.",1016,2,4,3,4,4,4,4,4,4,3,4,4,"Over the 14-day study period, six patients survived, but suffered mild issues. Two had sever issues and one have no results thus far. We are not able to determine if white blood cells have a direct effect on targeting and improving the symptoms of covid-19.",The results implicate white blood cells as a untherapeutic target for COVID-19.,58.28,73.17,50.84,0,9.7,0,8.4,6.8,9.2,12.63,8.69,13.73,11.4,8.3,11.3,12.18,10.7,13.44,9,12,4,7.5,7.833333333,7,9,12,4,11.35,9.56,11.47,8,10,14,
R_vrEMPFqrCVhDDO1,0,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells. ,1005,2,2,2,2,2,2,2,2,2,2,2,2,Exercise and diet was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells.,Intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by unblocking the viral entry to untargeted cells.,34.26,42.72,17.34,0,0,0,13.5,12.3,15.8,14.04,10.85,15.78,14.5,11.9,15.9,15.68,14.89,15.68,10,10,10,15,14,17,10,10,10,18,16,22,15,12,16,
R_vrEMPFqrCVhDDO1,0,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the control group.,1013,4,4,3,2,2,2,2,2,2,3.666666667,2,2,A need for mechanical ventilation occurred in 31% of the aNo Statement herekinra-treated group and 75% of the control group. Successful weaning from supplemental carbon was attained in 63% of the aNo Statement herekinra-treated group compared with 27% of the control group.,A need for mechanical ventilation occurred in 31% of the anakinra-treated group and 75% of the control group. Successful weaning from supplemental oxygen was attained in 63% of the anakinra-treated group compared with 27% of the uncontrolled group.,52.19,41.7,43.73,0,0,0,10.7,12.7,11.9,12.94,13.63,13.69,13.6,15.1,14.2,11.23,11.45,11.64,12,13,13,12.5,13.5,13,12,13,13,11.81,13.16,12.86,13,14,12,
R_vrEMPFqrCVhDDO1,0,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included fever, diarrhea, and cough. Our data confirm the importance of early identification of asymptomatic carriers.",1014,4,4,4,4,4,3,3,3,3,4,3.666666667,3,"We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included vomiting, headaches, and pain in lungs. Our data confirm the importance of early identification of asymptomatic carriers.","We evaluated 298 persons and identified twelve positive cases. 75% of the positive cases were asymptomatic, while only 25% of positive cases reported symptoms that included death. Our data confirm the importance of early identification of asymptomatic carriers.",32.19,31.58,33.2,15,15,14.6,12.2,12.4,11.8,15.25,15.01,15.12,13.2,13.3,12.6,11.25,11.69,11.33,15,15,14,11.16666667,11.5,10.33333333,15,15,14,15.24,15.02,14.55,12,12,15,
R_vrEMPFqrCVhDDO1,0,Microscopic abnormalities have been observed in both finger and toenails of patients with COVID-19.  This suggests that chilblains might be a symptom of COVID-19.,1017,4,4,4,4,4,4,4,4,4,4,4,4,Microscopic abnormalities have been observed in both finger and toeNo Statement hereils of patients with COVID-19. This suggests that measles might be a symptom of COVID-19.,Microscopic abnormalities have been observed in both finger and eyes of patients with COVID-19. This suggests that chilblains might be a symptom of COVID-19.,67.76,66.74,67.76,0,0,0,6.8,7.2,6.8,14.2,13.96,13.27,11.7,11.9,10.9,10.81,11.57,10.81,7,7,6,6,6.5,6,7,7,6,8.13,8.28,8.13,7,12,11,
R_vrEMPFqrCVhDDO1,0,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, and evidence of confirmed cases in the neighbourhood could help discriminate infected patients from uninfected.",1018,4,4,4,1,1,1,1,1,1,4,1,1,"We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (joint pain), household cluster, and evidence of confirmed cases in the state could help discrimiNo Statement herete infected patients from uninfected.","We found that age, symptom onset between 3 and 14 days, fever or history of fever, cough, sore throat, ageusia (loss of taste), anosmia (loss of smell), chest pain, myalgia (muscle aches and pains) and/or arthralgia (join pain), household cluster, and evidence of confirmed cases in the neighborhood could help discriminate infected patients from infected.",24.11,22.08,24.11,0,0,0,23.6,24.3,23.6,13.65,13.25,13.36,32.2,32.8,31.9,12.68,13.11,12.11,17,17,15,33.5,33.5,33.5,17,17,15,25.64,25.61,24.18,13,13,24,
